Uma Mahadevan-Velayos, MD
Associate Professor of Clinical Medicine; Director of Clinical Research, University of California San Francisco Center for Colitis and Crohn's Disease, San Francisco, California
Introduction
The approach to the standard of care for the management of Crohn's disease has changed dramatically over the past 10 years with the advent of biologic therapy. Although in the past therapy was predicated on control of symptoms, the goals of care have now changed to encompass sustained corticosteroid-free remission, mucosal healing, and a decrease in surgeries and hospitalizations. Biologic therapy, as of today, comprises either anti-tumor necrosis factor (TNF)-alpha agents (the chimeric IgG1 monoclonal antibody, infliximab; the fully human IgG1 monoclonal antibody, adalimumab; and the humanized antibody Fab' fragment, certolizumab pegol) or anti-alpha-4 integrin agents (the humanized monoclonal antibody, natalizumab). Infliximab is approved for reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy, and for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease.[1] Adalimumab is approved for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy, as well as for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.[2] Certolizumab pegol is approved for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.[3] Natalizumab is approved for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies and inhibitors of TNF-alpha.[4] With the more aggressive course of care come questions and concerns about the true benefit and safety of long-term biologic therapy. Although these questions are not fully answered at this time, what we do know about which patient will benefit from biologic therapy and how best to use these agents to increase efficacy and reduce adverse events is addressed in this clinical review.
Who Should Receive Biologic Therapy?
When the first biologic agent was approved for use in Crohn's disease in 1997, biologic therapy was considered a "last resort," when all other conventional therapies had failed. This was known as the "step-up" approach, where patients may start with conventional agents such as 5-aminosalicylates, antibiotics, or corticosteroids, move up to immunomodulators such as azathioprine/6-mercaptopurine or methotrexate, and only then consider anti-TNF-alpha therapy. This is not the case today, where a "top-down" approach is increasingly being used. In this strategy, the biologic agent may be the first therapy introduced in the appropriate patient. Although not all patients are candidates for anti-TNF-alpha therapy, those who are, will be best served with timely and judicious use of these agents to prevent complications rather than temporize them when they occur. So who is a candidate? Any patient with moderate-to-severe Crohn's disease is a candidate for biologic therapy, regardless of how long they have had disease -- 1 month or 10 years. Patients with corticosteroid-refractory disease, corticosteroid-dependent disease, or even those who are just candidates for corticosteroid therapy should be considered. Patients with significant perianal disease and high-risk postoperative disease should also be considered.
Crohn's disease has a heterogeneous presentation. In a study of 2000 patients with Crohn's disease assessing long-term disease behavior, a stricturing or penetrating complication developed in 60%. Twenty-year actuarial rates of inflammatory, stricturing, and penetrating disease were 12%, 18%, and 70%, respectively.[5] In a population-based study from Olmsted County, Minnesota, Faubion and colleagues[6] reported that only 43% of the Crohn's disease population from 1970 to 1993 had received corticosteroid therapy, suggesting that over 50% of the population has mild-to-moderate disease; these patients will never be candidates for corticosteroids, nor by extrapolation, anti-TNF-alpha therapy. However, at 1 year, of the 43% who received corticosteroids, prolonged response was seen in only 32%, corticosteroid dependence in 28%, and surgery in 38%, suggesting that those patients who receive corticosteroids or are candidates for corticosteroids are at risk for progression to more severe disease, and should be considered for anti-TNF-alpha therapy. This finding was supported by another study[7] that looked at factors on initial presentation that predicted a disabling course of Crohn's disease; 3 such factors were identified: corticosteroid use, perianal disease, and age < 40 years old.
In a study that examined the natural history of fistulas in Crohn's disease, fistulizing disease was found to occur in up to 33% of patients.[7,8] Infliximab,[9] adalimumab,[10] and certolizumab pegol[11] have all shown benefit for this difficult-to-manage complication. Any patient with significant perianal Crohn's disease is a candidate for anti-TNF-alpha therapy because it is the only treatment approved by the US Food and Drug Administration for this indication (specifically, infliximab), and aside from tacrolimus,* which is off-label for Crohn's disease, infliximab is the only agent to show benefit in a randomized trial with fistula closure as the primary endpoint.[12] Another group for which anti-TNF-alpha therapy has shown benefit where other conventional agents (aside from ornidazole* and metronidazole*) have not, is among patients with an ileocolonic resection. In a small randomized trial, infliximab was found to be superior to placebo for preventing endoscopic recurrence at 1 year (9.1% for infliximab compared with 84.6% in the placebo arm; P = .0006).[13] Patients with predictors of rapid disease recurrence after surgery (perforating disease, multiple surgeries) should also be considered strongly for anti-TNF-alpha therapy.[14]
How Should Biologic Therapy Be Optimized?
Several studies have shown that the introduction of biologic agents earlier in the disease course (before the development of complications), leads to better response. In the CHARM (Crohn's trial of the fully Human antibody Adalimumab for Remission Maintenance) trial,[15] adalimumab given at a dose of 40 mg weekly or every other week, was found to be superior to placebo in maintaining remission for 56 weeks in patients with active Crohn's disease. However, the earlier in a patient's disease course the drug was given, the better the response. Patients with disease of less than 2 years' duration had a remission rate of 51% at 56 weeks compared with 44% for those with disease of 2 to < 5 years' duration and about 35% for those with disease for ≥ 5 years.[16]
Data suggest that the use of biologic therapy in combination with immunomodulators is more effective than either therapy alone. Although subgroup analysis of the large clinical trials[17] did not show a benefit associated with the use of biologic therapy given in combination with immunomodulators over biologic therapy alone, 1 large prospective trial, SONIC[18] (Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease), did demonstrate benefit. In this study, 508 adult patients with moderate-to-severe Crohn's disease, median disease duration of 2.3 years, and no previous exposure to immunomodulators or biologic therapy, were randomly assigned to receive azathioprine* 2.5 mg/kg; infliximab 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks; or combination therapy* with both agents. Of the 169 patients who received combination therapy, 57% were in corticosteroid-free clinical remission at week 26 (the primary study endpoint) vs 44% of those who received infliximab alone (P = .02) and 30% of those who received azathioprine alone (P < .001 vs combination therapy, and P = .006 vs infliximab). At week 50, results were similar -- with 46%, 35%, and 24% of patients, respectively, in corticosteroid-free remission. At week 26, mucosal healing had occurred in 44% of patients who received combination therapy vs 30% of those who received infliximab alone (P = .06) and 17% of those who received azathioprine alone (P < .001 for the comparison with combination therapy, and P = .02 for the comparison with infliximab). Serious infections developed in 3.9% of patients in the combination therapy group, 4.9% of those in the infliximab monotherapy group, and in 5.6% of patients in the azathioprine group, suggesting that at 1 year, infectious complications were not increased by the use of combination therapy. Although the findings of this study are impressive, it is important to keep in mind that this does not answer the question of whether patients who fail to respond to azathioprine monotherapy will experience a similar benefit with combination therapy as patients who were naive to both therapies.
Associate Professor of Clinical Medicine; Director of Clinical Research, University of California San Francisco Center for Colitis and Crohn's Disease, San Francisco, California
Introduction
The approach to the standard of care for the management of Crohn's disease has changed dramatically over the past 10 years with the advent of biologic therapy. Although in the past therapy was predicated on control of symptoms, the goals of care have now changed to encompass sustained corticosteroid-free remission, mucosal healing, and a decrease in surgeries and hospitalizations. Biologic therapy, as of today, comprises either anti-tumor necrosis factor (TNF)-alpha agents (the chimeric IgG1 monoclonal antibody, infliximab; the fully human IgG1 monoclonal antibody, adalimumab; and the humanized antibody Fab' fragment, certolizumab pegol) or anti-alpha-4 integrin agents (the humanized monoclonal antibody, natalizumab). Infliximab is approved for reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy, and for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease.[1] Adalimumab is approved for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy, as well as for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.[2] Certolizumab pegol is approved for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.[3] Natalizumab is approved for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies and inhibitors of TNF-alpha.[4] With the more aggressive course of care come questions and concerns about the true benefit and safety of long-term biologic therapy. Although these questions are not fully answered at this time, what we do know about which patient will benefit from biologic therapy and how best to use these agents to increase efficacy and reduce adverse events is addressed in this clinical review.
Who Should Receive Biologic Therapy?
When the first biologic agent was approved for use in Crohn's disease in 1997, biologic therapy was considered a "last resort," when all other conventional therapies had failed. This was known as the "step-up" approach, where patients may start with conventional agents such as 5-aminosalicylates, antibiotics, or corticosteroids, move up to immunomodulators such as azathioprine/6-mercaptopurine or methotrexate, and only then consider anti-TNF-alpha therapy. This is not the case today, where a "top-down" approach is increasingly being used. In this strategy, the biologic agent may be the first therapy introduced in the appropriate patient. Although not all patients are candidates for anti-TNF-alpha therapy, those who are, will be best served with timely and judicious use of these agents to prevent complications rather than temporize them when they occur. So who is a candidate? Any patient with moderate-to-severe Crohn's disease is a candidate for biologic therapy, regardless of how long they have had disease -- 1 month or 10 years. Patients with corticosteroid-refractory disease, corticosteroid-dependent disease, or even those who are just candidates for corticosteroid therapy should be considered. Patients with significant perianal disease and high-risk postoperative disease should also be considered.
Crohn's disease has a heterogeneous presentation. In a study of 2000 patients with Crohn's disease assessing long-term disease behavior, a stricturing or penetrating complication developed in 60%. Twenty-year actuarial rates of inflammatory, stricturing, and penetrating disease were 12%, 18%, and 70%, respectively.[5] In a population-based study from Olmsted County, Minnesota, Faubion and colleagues[6] reported that only 43% of the Crohn's disease population from 1970 to 1993 had received corticosteroid therapy, suggesting that over 50% of the population has mild-to-moderate disease; these patients will never be candidates for corticosteroids, nor by extrapolation, anti-TNF-alpha therapy. However, at 1 year, of the 43% who received corticosteroids, prolonged response was seen in only 32%, corticosteroid dependence in 28%, and surgery in 38%, suggesting that those patients who receive corticosteroids or are candidates for corticosteroids are at risk for progression to more severe disease, and should be considered for anti-TNF-alpha therapy. This finding was supported by another study[7] that looked at factors on initial presentation that predicted a disabling course of Crohn's disease; 3 such factors were identified: corticosteroid use, perianal disease, and age < 40 years old.
In a study that examined the natural history of fistulas in Crohn's disease, fistulizing disease was found to occur in up to 33% of patients.[7,8] Infliximab,[9] adalimumab,[10] and certolizumab pegol[11] have all shown benefit for this difficult-to-manage complication. Any patient with significant perianal Crohn's disease is a candidate for anti-TNF-alpha therapy because it is the only treatment approved by the US Food and Drug Administration for this indication (specifically, infliximab), and aside from tacrolimus,* which is off-label for Crohn's disease, infliximab is the only agent to show benefit in a randomized trial with fistula closure as the primary endpoint.[12] Another group for which anti-TNF-alpha therapy has shown benefit where other conventional agents (aside from ornidazole* and metronidazole*) have not, is among patients with an ileocolonic resection. In a small randomized trial, infliximab was found to be superior to placebo for preventing endoscopic recurrence at 1 year (9.1% for infliximab compared with 84.6% in the placebo arm; P = .0006).[13] Patients with predictors of rapid disease recurrence after surgery (perforating disease, multiple surgeries) should also be considered strongly for anti-TNF-alpha therapy.[14]
How Should Biologic Therapy Be Optimized?
Several studies have shown that the introduction of biologic agents earlier in the disease course (before the development of complications), leads to better response. In the CHARM (Crohn's trial of the fully Human antibody Adalimumab for Remission Maintenance) trial,[15] adalimumab given at a dose of 40 mg weekly or every other week, was found to be superior to placebo in maintaining remission for 56 weeks in patients with active Crohn's disease. However, the earlier in a patient's disease course the drug was given, the better the response. Patients with disease of less than 2 years' duration had a remission rate of 51% at 56 weeks compared with 44% for those with disease of 2 to < 5 years' duration and about 35% for those with disease for ≥ 5 years.[16]
Data suggest that the use of biologic therapy in combination with immunomodulators is more effective than either therapy alone. Although subgroup analysis of the large clinical trials[17] did not show a benefit associated with the use of biologic therapy given in combination with immunomodulators over biologic therapy alone, 1 large prospective trial, SONIC[18] (Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease), did demonstrate benefit. In this study, 508 adult patients with moderate-to-severe Crohn's disease, median disease duration of 2.3 years, and no previous exposure to immunomodulators or biologic therapy, were randomly assigned to receive azathioprine* 2.5 mg/kg; infliximab 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks; or combination therapy* with both agents. Of the 169 patients who received combination therapy, 57% were in corticosteroid-free clinical remission at week 26 (the primary study endpoint) vs 44% of those who received infliximab alone (P = .02) and 30% of those who received azathioprine alone (P < .001 vs combination therapy, and P = .006 vs infliximab). At week 50, results were similar -- with 46%, 35%, and 24% of patients, respectively, in corticosteroid-free remission. At week 26, mucosal healing had occurred in 44% of patients who received combination therapy vs 30% of those who received infliximab alone (P = .06) and 17% of those who received azathioprine alone (P < .001 for the comparison with combination therapy, and P = .02 for the comparison with infliximab). Serious infections developed in 3.9% of patients in the combination therapy group, 4.9% of those in the infliximab monotherapy group, and in 5.6% of patients in the azathioprine group, suggesting that at 1 year, infectious complications were not increased by the use of combination therapy. Although the findings of this study are impressive, it is important to keep in mind that this does not answer the question of whether patients who fail to respond to azathioprine monotherapy will experience a similar benefit with combination therapy as patients who were naive to both therapies.